Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.

New medtech regulatory policy, technology adoption challenges and NHS architecture changes under the new Health and Care Act will give system UK users much to ponder over this summer.